Overview

To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions

Status:
Completed
Trial end date:
2019-04-22
Target enrollment:
Participant gender:
Summary
This study is a multicenter, Open-label, Parallel, Phase 2 Clinical Trial in 6 weeks for screening, once Investigational product injection, Follow up visit.
Phase:
Phase 2
Details
Lead Sponsor:
Hanlim Pharm. Co., Ltd.
Treatments:
Charcoal